Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs

PLoS Pathogens

Volumn 6, Issue 6, 2010, Pages

  Berger, Edward A ^a   Pastan, Ira ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; IMMUNOTOXIN; COMPLEMENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; CYTOTOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; IMMUNOLOGY; PATHOGENICITY; VIREMIA;

ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMPLEMENT SYSTEM PROTEINS; HIV; HIV INFECTIONS; HUMANS; IMMUNOTOXINS; VIREMIA;

EID: 77954685640     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000803     Document Type: Article

References (68)

1. Broder S (2010) The development of antiretrovi-ral therapy and its impact on the HIV-1/AIDS pandemic. Antivir Res 85: 1-18.
2. Contreras X, Lenasi T, Peterlin BM (2006) HIV latency: present knowledge and future directions. Future Virol 1: 733-745.
3. Geeraert L, Kraus G, Pomerantz RJ (2008) Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med 59: 487-501.
4. Shen L, Siliciano RF (2008) Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 122: 22-28.
5. Stevenson M (2008) Can HIV be cured? Sci Am 299: 78-83.
6. Fauci A The future of AIDS research. XVII International AIDS Conference; 3-8 August 2008; Mexico City, Mexico. Avaliable: http://www.kaisernetwork.org/health_cast/hcast_in-dex.cfm?display=detail&hc=2912. Accessed 12 May 2010.
7. Marsden MD, Zack JA (2009) Eradication of HIV: current challenges and new directions. J Antimicrob Chemother 63: 7-10.
8. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, et al. (2009) The challenge of finding a cure for HIV infection. Science 323: 1304-1307.
9. Murphy RL, Autran B, Katlama C, Brucker G, Debre P, et al. (2009) A step ahead on the HIV collaboratory. Science 324: 1264-1265.
10. Strebhardt K, Ullrich A (2008) Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 8: 473-480.
11. Fuchs H, Bachran C (2009) Targeted tumor therapies at a glance. Curr Drug Targ 10: 89-93.
12. Duvic M, Talpur R (2008) Optimizing denileukin diftitox (Ontak (R)) therapy. Future Oncol 4: 457-469.
13. Stasi R, Evangelista ML, Buccisano F, Venditti A, Amadori S (2008) Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev 34: 49-60.
14. Dadachova E, Casadevall A (2008) Host and microbial cells as targets for armed antibodies in the treatment of infectious diseases. Curr Opin Investig Drugs 9: 184-188.
15. Gallo RC, Montagnier L (2003) Retrospective: the discovery of HIV as the cause of AIDS. N Eng J Med 349: 2283-2285.
16. Chaudhary VK, Mizukami T, Fuerst TR, FitzGerald DJ, Moss B, et al. (1988) Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature 335: 369-372.
17. Till MA, Ghetie V, Gregory T, Patzer EJ, Porter JP, et al. (1988) HIV-infected cells are killed by rCD4-ricin A chain. Science 242: 1166-1168.
18. Pincus SH, Wehrly K, Chesebro B (1989) Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. J Immunol 142: 3070-3075.
19. Aullo P, Alcami J, Popoff MR, Klatzmann DR, Murphy JR, et al. (1992) A recombinant diphtheria toxin related human CD4 fusion protein specifically kills HIV infected cells which express gp120 but selects fusion toxin resistant cells which carry HIV. EMBO J 11: 575-583.
20. Finberg RW, Wahl SM, Allen JB, Soman G, Strom TB, et al. (1991) Selective elimination of HIV-1-infected cells with an interleukin-2 receptor-specific cytotoxin. Science 252: 1703-1705.
21. Zhang L, Waters C, Nichols J, Crumpacker C (1992) Inhibition of HIV-1 RNA Production by the Diphtheria Toxin- Related IL-2 Fusion Proteins DAB(486)IL-2 and DAB(389)IL-2. J Acquir Immune Defic Syndr 5: 1181-1187.
22. - T-cells in acute HIV-infection invitro. J Immunol 150: 5202-5208.
23. McCoig C, Van Dyke G, Chou CS, Picker LJ, Ramilo O, et al. (1999) An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro. Proc Natl Acad Sci U S A 96: 11482-11485.
24. Wolf P, Elsasser-Beile U (2009) Pseudomonas exotoxin A: From virulence factor to anti-cancer agent. Int J Med Microbiol 299: 161-176.
25. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6: 559-565.
26. Berger EA, Chaudhary VK, Clouse KA, Jaraquemada D, Nicholas JA, et al. (1990) Recombinant CD4-Pseudomonas exotoxin hybrid protein displays HIV-specific cytotoxicity without affecting MHC class II-dependent functions. AIDS Res Hum Retroviruses 6: 795-804.
27. Ashorn P, Moss B, Berger EA (1992) Activity of CD4-Pseudomonas exotoxin against cells express-ing diverse forms of the HIV and SIV envelope glycoproteins. J Acquir Immune Defic Syndr 5: 70-77.
28. Bera TK, Kennedy PE, Berger EA, Barbas CFI, Pastan I (1998) Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein. Mol Med 4: 384-391.
29. Berger EA, Clouse KA, Chaudhary VK, Chakrabarti S, FitzGerald DJ, et al. (1989) CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses. Proc Natl Acad Sci U S A 86: 9539-9543.
30. Ashorn P, Moss B, Weinstein JN, Chaudhary VK, FitzGerald DJ, et al. (1990) Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse tran-scriptase inhibitors. Proc Natl Acad Sci U S A 87: 8889-8893.
31. Ashorn P, Englund G, Martin MA, Moss B, Berger EA (1991) Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages. J Infect Dis 163: 703-709.
32. Kennedy PE, Moss B, Berger EA (1993) Primary HIV-1 isolates refractory to neutralization by soluble CD4 are potently inhibited by CD4-Pseudomonas exotoxin. Virology 192: 375-379.
33. Verhoef J, Gekker G, Erice A, Peterson PK, Balfour HH (1992) Quantitative assay for testing susceptibility of HIV isolates to zidovudine and sCD4 (178)-PE40. Eur J Clin Microbiol Infect Dis 11: 715-721.
34. Winters MA, Merigan TC (1993) Continuous Presence of CD4-PE40 Is Required for Antiviral Activity Against Single-Passage HIV Isolates and Infected Peripheral Blood Mononuclear Cells. AIDS Res Hum Retroviruses 9: 1091-1096.
35. Gorry PR, Churchill M, Crowe SM, Cunningham AL, Gabuzda D (2005) Pathogen- esis of macrophage tropic HIV-1. Curr HIV Res 3: 53-60.
36. Coleman CM, Wu L (2009) HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology 6: 51.
37. Davey RT, Boenning CM, Herpin BR, Batts DH, Metcalf JA, et al. (1994) Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. J Infect Dis 170: 1180-1188.
38. Ramachandran RV, Katzenstein DA, Wood R, Batts DH, Merigan TC (1994) Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons. J Infect Dis 170: 1009-1013.
39. Berger EA, Moss B, Pastan I (1998) Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART. Proc Natl Acad SciUSA 95: 11511-11513.
40. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, et al. (2001) Efficacy of the anti-CD22 recombinant immu-notoxin BL-22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345: 241-247.
41. Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, FitzGerald DJP, et al. (2009) Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 27: 2983-2990.
42. Barbas CF, Hu D, Dunlop N, Sawyer L, Cababa D, et al. (1994) In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci U S A 91: 3809-3813.
43. Kennedy PE, Bera TK, Wang QC, Gallo M, Wagner W, et al. (2006) Anti-HIV-1 immuno-toxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macro-phages, and negligible hepatotoxicity in macaques. J Leukoc Biol 80: 1175-1182.
44. Onda M, Nagata S, Tsutsumi Y, Vincent JJ, Wang QC, et al. (2001) Lowering the isoelectric point of the Fv portion of recombinant immuno-toxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res 61: 5070-5077.
45. Goldstein H, Pettoello-Mantovani M, Bera TK, Pastan IH, Berger EA (2000) Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-scid-hu mice. J Infect Dis 181: 921-926.
46. Uberla K, Stahlhennig C, Bottiger D, Matzrensing K, Kaup FJ, et al. (1995) Animal model for the therapy of acquired-immunodefi ciency syndrom with reverse transcriptase inhib itors. Proc Natl Acad Sci U S A 92: 8210-8214.
47. Igarashi T, Brown CR, Endo Y, Buckler-White A, Plishka R, et al. (2001) Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4(+) t cells by a highly pathogenic simian immunodeficiency virus/hiv type 1 chimera (shiv): implications for hiv-1 infections of humans. Proc Natl Acad Sci U S A 98: 658-663.
48. Ambrose Z, Palmer S, Boltz VF, Kearney M, Larsen K, et al. (2007) Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol 81: 12145-12155.
49. Van Rompay KKA, Johnson JA, Blackwood EJ, Singh RP, Lipscomb J, et al. (2007) Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology 4: 25.
50. Dinoso JB, Rabi SA, Blankson JN, Gama L, Mankowski JL, et al. (2009) A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 83: 9247-9257.
51. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, et al. (2009) Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 106: 9403-9408.
52. Jones J, McMahon D, Wiegand A, Kearney M, Palmer S, et al. (2009);No decrease in residual viremia during raltegravir intensification in patients on standard ART. 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Canada. CROI 2009. [Abstract 423b].
53. Buzon M, Llibre J, Domingo P, Paredes R, Palmer S, et al. (2009);Transient increase in episomal viral cDNA following raltegravir intensification of a stable HAART Regimen. 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Canada. CROI 2009. [Abstract 423a].
54. Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, et al. (2006) Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4(+) T cells. J Virol 80: 6441-6457.
55. Brennan TP, Woods JO, Sedaghat AR, Siliciano JD, Siliciano RF, et al. (2009) Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4(+) T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol 83: 8470-8481.
56. Brooks DG, Hamer DH, Arlen PA, Gao LY, Bristol G, et al. (2003) Molecular characterization, reactivation, and depletion of latent HIV. Immunity 19: 413-423.
57. Marsden MD, Xu J, Hamer D, Zack JA (2008) Activating stimuli enhance immunotoxin-mediat-ed killing of HIV-infected macrophages. AIDS Res Hum Retroviruses 24: 1399-1404.
58. Johansson S, Goldenberg DM, Griffiths GL, Wahren B, Hinkula J (2006) Elimination of HIV-1 infection by treatment with a doxorubi-cin-conjugated anti-envelope antibody. AIDS 20: 1911-1915.
59. Dadachova E, Patel MC, Toussi S, Apostolidis C, Morgenstern A, et al. (2006) Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med 3: e427. doi:10.1371/journal.pmed.0030427.
60. Onda M, Beers R, Xiang L, Nagata S, Wang QC, et al. (2008) An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A 105: 11311-11316.
61. McHugh L, Hu S, Lee BK, Santora K, Kennedy PE, et al. (2002) Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis. J Biol Chem 277: 34383-34390.
62. Pincus SH, Fang H, Wilkinson RA, Marcotte TK, Robinson JE, et al. (2003) In vivo efficacy of anti-glycoprotein 41, but not anti- glycoprotein 120, immunotoxins in a mouse model of hiv infection. J Immunol 170: 2236-2241.
63. Root MJ, Hamer DH (2003) Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein. Proc Natl Acad Sci U S A 100: 5016-5021.
64. Montefiori D, Sattentau Q, Flores J, Esparza J, Mascola J (2007) Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med 4: e348. doi:10.1371/journal.pmed.0040348.
65. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
66. Brenchley JM, Douek DC (2008) HIV infection and the gastrointestinal immune system. Mucosal Immunol 1: 23-30.
67. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, et al. (2008) Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 197: 714-720.
68. Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, et al. (2008) Inferior clinical outcome of the CD4(+) cell count guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4(+) cell counts and HIV RNA levels during follow-up. J Infect Dis 197: 1145-1155.